Predicting and preventing the emergence of antiviral drug resistance in HSV-2

Article metrics

Abstract

Genital herpes, caused by herpes simplex virus, is the most prevalent sexually transmitted disease worldwide. In many developing countries genital herpes is untreated, and in the United States only 10% of cases are treated. We present a mathematical model that we use as a health policy tool to predict the levels of antiviral drug resistance that would emerge, if treatment rates were increased, and to identify the key factors in determining the emergence of drug resistance. We use our results to suggest control measures for herpes epidemics that would prevent the emergence of substantial levels of antiviral drug resistance.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Fleming, D.T. et al. Herpes Simplex Virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337, 1105–11 (1997).

  2. 2

    Nahmias, A.J., Lee, F.K. & Beckman-Nahmias, S. Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world. Scand. J. Infect. Dis. 69, 19–36 (1990).

  3. 3

    Oberle, M.W. et al. Herpes simplex virus type 2 antibodies: high prevalence in monogamous women in Costa Rica. Amer. J. Trop. Med. Hyg 41, 224–229 (1989).

  4. 4

    Marchant, J. & Roe, A. Genital herpes: recognizing and addressing patients's needs. Herpes Journal 4, 36–41 (1997).

  5. 5

    Wildy, P., Field, H.J. & Nash, A.A. Classical herpes latency revisited. Soc. Gen. Microbiol. Symp. 33, 133–167 (1982).

  6. 6

    Mertz, G.L., Schmidt, O. & Jourden, J.L. Frequency of acquisition of first episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex. Tramm. Dis. 12, 33–39 (1985).

  7. 7

    Reichman, R.C. et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. J. Am. Med. Assoc. 251, 2103–2107 (1984).

  8. 8

    Straus, S.E. et al. Suppression offrequently recurring genital herpes: a placebo-controlled double-blind trial of oralacyclovir. N. Engl. J. Med. 310, 1545–1550 (1984).

  9. 9

    Collins, P. & Darby, G. Laboratory studies of herpes simplex virus strains resistant to Acyclovir. Rev. Med. Virol. 1, 19–28 (1991).

  10. 10

    Larder, B.A. & Darby, G. Selection and characteristics of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA ploymerase activities. Virology 146, 262–271 (1985).

  11. 11

    Darby, G., Field, H.J. & Salisbury, S.A. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature 289, 81–83 (1981).

  12. 12

    Safrin, S. et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N. Engl. J. Med. 325, 551–555 (1991).

  13. 13

    Hook, E.W. et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J. Infect. Dis. 165, 251–255 (1992).

  14. 14

    Blower, S.M. & McLean, A.R. Prophylactic vaccines, risk behavior change and the probability of eradicating HIV in San Francisco. Science 265, 1451–1454 (1994).

  15. 15

    Blower, S.M., Small, P.M. & Hopewell, P. Control strategies for tuberculosis epidemics: new models for old problems. Science 273, 497–500 (1996).

  16. 16

    Blower, S.M. & Gerberding, J.L. The Dynamics of Drug Resistant Tuberculosis: A Theoretical Framework. J. Mol. Med. (In the press).

  17. 17

    Whitely, R.J. & Gnann, J.W. Acyclovir: a decade later. New Engl. J. Med. 327, 782–789 (1992).

  18. 18

    Kaplan, E.H. Economic evaluation and HIV prevention community planning - A policy analysts's perspective. in Handbook of HIV Prevention Policy Analysis (ed. Holtgrave,D.) (In the press).

  19. 19

    Wald, A., Zeh, J., Barnum, G., Davis, L.G. & Corey, L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann. Intern. Med. 124, 8–15 (1996).

  20. 20

    Safrin, S. Cherrington, J. & Jaffe, H.S. Clinical use of cidofovir. Rev. Med. Virol. 7, 145–156(1997).

  21. 21

    Iman, R.L. & Helton, J.C. An investigation of uncertainty and sensitivity analysis techniques for computer models. Risk Analysis 8, 71–90 (1980).

  22. 22

    Mckay, M.D., Beckman, R.J. & Conover, W.J. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics 21, 239–245 (1979).

  23. 23

    Blower, S.M., Hartel, D., Dowlatabadi, H., May, R.M. & Anderson, R.M. Drugs, sex and HIV: a mathematical model for New York City. Phil.Trans. Roy Soc. Series B 321, 171–187(1991).

  24. 24

    Blower, S.M. & Dowlatabadi, H. Sensitivity and Uncertainty Analysis of complex models of disease transmission: an HIV model, as an example. Int. Statist. Rev. 62, 229–243 (1994).

  25. 25

    Blower, S.M. et al. The intrinsic transmission dynamics of tuberculosis epidemics. NatureMed. 1, 815–821 (1995).

  26. 26

    Sanchez, M.A. & Blower, S.M. Uncertainty and sensitivity analysis of the basic reproductive rate: Tuberculosis as an example. Am. J. Epidemiol. 145, 1127–1138 (1997).

  27. 27

    Porco, T.C. & Blower, S.M. Quantifying the intrinsic transmission dynamics of tuberculosis. Theor. Popul. Biol. (in the press).

  28. 28

    Porco, T.C. A mathematical model of the ecology of Lyme disease. IMAJ. Math. Appl. Med. Biol. (in the press).

  29. 29

    Kost, R.G., Hill, E.L., Tigges, M. & Straus, S.E. Recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N. Engl. J. Med. 329, 1777–1782 (1993).

  30. 30

    Englund, J.A. et al. Herpes simplex virus resistant to acyclovir. Ann. Intern. Med. 112, 416–422 (1990).

  31. 31

    Wade, J.C., McLaren, C. & Meyers, J.D. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J. Infect. Dis. 148, 1077–1082 (1983).

  32. 32

    Barry, D.W., Nusinoff-Lehrman, S., Ellis, M.N., Biron, K.K. & Furman, P.A. Viral resistance, clinical experience. Scand. I. Infec. Dis. Suppl. 47, 155–164 (1985).

  33. 33

    Mertz, G.J., Benedetti, J., Ashley, R., Selke, S. & Corey, L. Risk factors for the sexual transmission of genital herpes. Ann. Intern. Med. 116, 197–202 (1992).

  34. 34

    Mertz, G.J. et al. Transmission of genital herpes in couples with one asymptomatic and one asymptomatic partner: a prospective study. J. Infect. Dis. 157, 1169–77 (1988).

  35. 35

    Wald, A., Zeh, J., Selke, S., Ashley, R.L. & Corey, L. Virologic characteristics of sub-clinical and symptomatic genital herpes infections. N. Engl. J. Med. 333, 770–775 (1995).

  36. 36

    Benedetti, J., Corey, L. & Ashley, R. Recurrence rates of genital herpes after acquisition of symptomatic first episode infection. Ann. Intern. Med. 121, 847–54 (1994).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Blower, S., Porco, T. & Darby, G. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat Med 4, 673–678 (1998) doi:10.1038/nm0698-673

Download citation

Further reading